All major optical building blocks of QKD integrated on photonic chips, enabling scalable, cost-efficient quantum-secure communications for real-world networks Fürth, Germany — 2026-03-16 — KEEQuant today announced the launch of its commercial-grade chip-scale QKD technology, marking a major advance in quantum-secure communications. This breakthrough redefines the economics and practicality of quantum key distribution by replacing bulky, complex optical assemblies with photonic integration and turning quantum-safe key exchange into a realistic network upgrade for telecom operators, data center providers and critical infrastructure organizations. The result is smaller, more scalable and more cost-efficient systems that preserve compatibility with existing fiber environments and established encryption solutions, making broader adoption far more practical for organizations preparing their infrastructure for the long-term cryptographic risks posed by quantum computing. “For years, QKD has been seen as strategically important, but too complex and too costly for broad deployment,” said Imran Khan, Managing Director at KEEQuant. “Bringing QKD to the chip scale changes that. It gives quantum-safe key exchange the economics and practicality it needs to move into real-world networks.” Based on this technology, KEEQuant will begin shipments to first customers later this year. Why chip-scale QKD is a market inflection point: A dramatically lower system-cost basis fundamentally changes the economics of QKD Wider accessibility makes quantum-safe key exchange viable for many more applications and customers Broader market adoption becomes possible as QKD moves beyond premium niche deployments New business models and integration opportunities open up across communications, security and quantum-network infrastructure Technically, the milestone is the integration and system-level validation of the major optical building blocks required for QKD on photonic chips. Using commercial PICs, KEEQuant brought transmitter and receiver lasers, modulation, receiver optics and detection to the chip scale, replacing bulky optical assemblies with a compact photonic architecture. Beyond miniaturization alone, this establishes the engineering basis for repeatable packaging, manufacturable system design and reliable system-level integration of chip-scale QKD building blocks. With this launch, KEEQuant moves quantum-safe communications from research and pilot deployments into commercially viable infrastructure. About KEEQuant KEEQuant GmbH is a start-up company specializing in quantum-secure communications. Its core business is the development and sale of Quantum Key Distribution (QKD) systems, Key Management Systems (KMS), and hybrid applications of post-quantum cryptography (PQC). The miniaturization of QKD technology onto photonic chips, together with certification and approval of the overall system, forms the foundation for long-term secure communications. This helps ensure that users’ security-critical data flows remain protected against unauthorized access even in future threat scenarios, such as attacks using powerful quantum computers. Funding This work has received funding through the SEQRET project under the European Union’s Digital Europe Programme, within the framework of EuroQCI, under call DIGITAL-2021-QCI-01-INDUSTRIAL (Project ID: 101091591). SEQRET advances secure and industrialized QKD systems for European telecommunication networks, including photonic integration, manufacturability, and certification readiness.   Media Contact press@keequant.com www.keequant.com Address: KEEQuant GmbH, Gebhardtstrasse 28, 90762 Fürth, Germany

Rotonium will participate as a speaker at the conference “Quantum Computing in Life Sciences”, taking place in Milan on 16 April 2026. The event will explore the practical impact of quantum computing on the future pharmaceutical industry, spanning key themes such as R&D for new molecules and drugs, the adoption of AI and Digital Twins for personalized therapy simulations, the digitalization of pharma production, and the acceleration of time-to-market in increasingly dynamic market scenarios. With quantum computing now entering strategic roadmaps and attracting significant industrial investment—especially through synergies with AI and Machine Learning—the conference will bring together experts from medicine, pharma companies, academia, data science, quantum platform providers, quantum-AI developers, policy makers, venture capital, and consulting to outline the state of the art and emerging scenarios, partnerships, and patient benefits. During the program, Roberto Siagri (CEO, Rotonium) will deliver a talk on the advantages of photonic quantum accelerators for molecule development and genome analysis, highlighting compact, room-temperature solutions designed for integration into hybrid computing workflows—from industrial workstations to scaling toward private data centers. For more information and registration click here.

Kvantify is excited to announce the successful second close of its total €7M funding round. The long-term investors European Innovation Council Fund (EIC) and Danish-based Delphinus Venture Capital support the Company’s mission to transform molecular discovery by coupling quantum and classical computing. “We are thrilled to have the EIC Fund and Delphinus VC on board for this round extension. Their support empowers us to accelerate innovation and strengthens Europe’s position in quantum technology,” says Dr. Jörg Weiser, Executive Chairperson at Kvantify. Technology with immense potential Quantum computing has the potential to solve problems that are currently too complex for even the most powerful classical computers. As the technology matures, it will unlock breakthroughs in areas such as drug discovery and general molecular design. Many drug discovery challenges relate to molecular simulation and require solving quantum mechanical equations that scale exponentially with molecular size – this is at the heart of what the concept of quantum computing was originally invented to handle. As quantum hardware and algorithms mature, these capabilities may dramatically lower drug development attrition rates, lower R&D costs, and open the door to discovering entirely new classes of medicines. “Supporting pioneering technologies is at the heart of our mission. Kvantify’s work at the intersection of quantum computing and life sciences represents a transformative opportunity for Europe to lead in next-generation innovation. We are glad to play a role in accelerating this vision,” says Svetoslava Georgieva, Chair of the EIC Fund Board. Investment set to expand on market presence and business development In November 2025, Kvantify launched Qrunch, a technology for running quantum chemistry on real quantum computers, strengthening the platform to accelerate drug discovery. The next step will be to make this breakthrough technology available to users in the relevant domains to ensure uptake where it matters the most. This is the place at which visionary technologies meet real-world customer needs. Qrunch allows end users to run realistic workflows with present quantum hardware. With this investment, Kvantify will be able to propel its roadmap as the leading company in coupling quantum and classical computing, as well as increasing collaborative partnerships with drug discovery organisations to make the biggest impact for customers. “We see Kvantify as a key player in unlocking the potential of quantum computing for real-world applications in drug discovery and molecular design. This investment reflects our confidence in their team, technology, and ability to deliver impact in a rapidly evolving market,” says Mathias Lorenz, Managing Partner at Delphinus VC. About EIC Fund The European Innovation Council Fund from the European Commission is a deep tech investor across all technologies. The EIC Fund aims to fill a critical financing gap, to support companies in the development and commercialisation of disruptive technologies. With its large network of capital providers and strategic partners it shares risk and crowds in market players. More information: https://eic.ec.europa.eu/eic-fund_en About Delphinus Venture Capital • Established in 2025 • Initial fund of €80 million • Investors: Aarhus University Research Foundation, HEARTLAND, Norlys, and Salling Group • Focus: Research-heavy innovation and deep tech More information: https://delphinus.vc/

An inverted tabletop dilution refrigerator, that can achieve millikelvin temperatures, has long been the holy grail for fast-turnaround quantum technology development. Especially useful for fast and affordable quantum chip testing. In 2023 Quantum Delta NL, an organization funded by the Dutch National Growth Fund, awarded funding to companies Leiden Cryogenics and Orange Quantum Systems. They set out to develop a compact, fast turn-around cryostat for quantum applications.   A fast turn-around ‘mini-fridge’ for quantum applications Three years after the conception of the ‘mini-fridge’ for quantum R&D, Leiden Cryogenics (LC) successfully finalized a prototype in the Quper project. At the APS Global Physics Summit, LC will unveil a new product based on the Quper project. The company is promising a compact and affordable cryogenic system, capable of cooling a sample to below 25 millikelvin and returning it to room temperature in less than 24 hours. The project tested a new inverted fridge design, allowing for ergonomic tabletop access for operators. By shrinking all components, including the heat switch and dilution unit, a much faster cooldown is possible. Achieved without the need for liquid nitrogen and with a significantly lower helium-3 requirement. Sasha Usenko, Leiden Cryogenics CTO: “Fast, compact, simple, but fully functional dilution refrigerators (be it for quantum chip testing and development, optical or beamline experiments, etc…) have been a popular request from our customers for many years and now we are finally ready to fulfill it.”   Testing of quantum devices and system control In 2025, project partner Orange Quantum Systems used the prototype cryogenic system for testing Travelling Wave Parametric Amplifiers. To remotely monitor, control, and automate the Quper fridge, the project introduced a new Leiden Cryogenics back‑end for SubZero, the cryogenic control software that runs on OrangeQS Juice. This was made possible thanks to the flexible and extensible nature of the Juice OS. Koushik Kumaran, product owner at OrangeQS: “The fact that a fridge manufacturer has developed a new system with Juice as the operating system is a huge indicator of reliability.”   About the project partners This project was made possible by Quantum Delta NL. About LC: Leiden Cryogenics has been a leader in extreme low temperature techniques for over 30 years. Founded in 1992 by Prof. Dr. Giorgio Frossati as a spin-off from the University of Leiden, started in a small lab with room for only one dilution refrigerator. Now 34 years later, Leiden Cryogenics is still working on various cryogenic innovations day and night. With a flexible and dedicated team of cryogenic experts, Leiden Cryogenics provides a range of solutions for your cryogenic applications.   About OrangeQS: Orange Quantum Systems develops advanced solutions for automated testing and characterization of quantum chips, enabling the transition from lab-scale devices to industrial-grade quantum computers. Based in Delft, the Netherlands, the company leverages deep academic roots and engineering excellence to serve the global quantum ecosystem.